Curcumin in hepatobiliary disease

Pharmacotherapeutic properties and emerging potential clinical applications

Robert W. Hu, Elizabeth J. Carey, Keith Lindor, James H. Tabibian

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Curcumin, an aromatic phytoextract from the turmeric (Curcuma longa) rhizome, has been used for centuries for a variety of purposes, not the least of which is medicinal. A growing body of evidence suggests that curcumin has a broad range of potentially therapeutic pharmacological properties, including anti-inflammatory, anti-fibrotic, and anti-neoplastic effects, among others. Clinical applications of curcumin have been hampered by quality control concerns and limited oral bioavailability, although novel formulations appear to have largely overcome these issues. Recent in vitro and in vivo studies have found that curcumin’s cytoprotective and other biological activities may play a role in an array of benign and malignant hepatobiliary conditions, including but not limited to non-alcoholic fatty liver disease, cholestatic liver disease (e.g. primary sclerosing cholangitis), and cholangiocarcinoma. Here we provide an overview of fundamental principles, recent discoveries, and potential clinical hepatobiliary applications of this pleiotropic phytocompound.

Original languageEnglish (US)
Pages (from-to)835-841
Number of pages7
JournalAnnals of Hepatology
Volume16
Issue number6
DOIs
StatePublished - Nov 1 2017

Fingerprint

Curcumin
Curcuma
Sclerosing Cholangitis
Rhizome
Cholangiocarcinoma
Quality Control
Biological Availability
Liver Diseases
Anti-Inflammatory Agents
Pharmacology
Therapeutics

Keywords

  • Antioxidants
  • Complementary medicine
  • Liver diseases
  • Phytotherapy

ASJC Scopus subject areas

  • Hepatology

Cite this

Curcumin in hepatobiliary disease : Pharmacotherapeutic properties and emerging potential clinical applications. / Hu, Robert W.; Carey, Elizabeth J.; Lindor, Keith; Tabibian, James H.

In: Annals of Hepatology, Vol. 16, No. 6, 01.11.2017, p. 835-841.

Research output: Contribution to journalArticle

Hu, Robert W. ; Carey, Elizabeth J. ; Lindor, Keith ; Tabibian, James H. / Curcumin in hepatobiliary disease : Pharmacotherapeutic properties and emerging potential clinical applications. In: Annals of Hepatology. 2017 ; Vol. 16, No. 6. pp. 835-841.
@article{680b4f543c28435ca0abdb4d242e4aec,
title = "Curcumin in hepatobiliary disease: Pharmacotherapeutic properties and emerging potential clinical applications",
abstract = "Curcumin, an aromatic phytoextract from the turmeric (Curcuma longa) rhizome, has been used for centuries for a variety of purposes, not the least of which is medicinal. A growing body of evidence suggests that curcumin has a broad range of potentially therapeutic pharmacological properties, including anti-inflammatory, anti-fibrotic, and anti-neoplastic effects, among others. Clinical applications of curcumin have been hampered by quality control concerns and limited oral bioavailability, although novel formulations appear to have largely overcome these issues. Recent in vitro and in vivo studies have found that curcumin’s cytoprotective and other biological activities may play a role in an array of benign and malignant hepatobiliary conditions, including but not limited to non-alcoholic fatty liver disease, cholestatic liver disease (e.g. primary sclerosing cholangitis), and cholangiocarcinoma. Here we provide an overview of fundamental principles, recent discoveries, and potential clinical hepatobiliary applications of this pleiotropic phytocompound.",
keywords = "Antioxidants, Complementary medicine, Liver diseases, Phytotherapy",
author = "Hu, {Robert W.} and Carey, {Elizabeth J.} and Keith Lindor and Tabibian, {James H.}",
year = "2017",
month = "11",
day = "1",
doi = "10.5604/01.3001.0010.5273",
language = "English (US)",
volume = "16",
pages = "835--841",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "6",

}

TY - JOUR

T1 - Curcumin in hepatobiliary disease

T2 - Pharmacotherapeutic properties and emerging potential clinical applications

AU - Hu, Robert W.

AU - Carey, Elizabeth J.

AU - Lindor, Keith

AU - Tabibian, James H.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Curcumin, an aromatic phytoextract from the turmeric (Curcuma longa) rhizome, has been used for centuries for a variety of purposes, not the least of which is medicinal. A growing body of evidence suggests that curcumin has a broad range of potentially therapeutic pharmacological properties, including anti-inflammatory, anti-fibrotic, and anti-neoplastic effects, among others. Clinical applications of curcumin have been hampered by quality control concerns and limited oral bioavailability, although novel formulations appear to have largely overcome these issues. Recent in vitro and in vivo studies have found that curcumin’s cytoprotective and other biological activities may play a role in an array of benign and malignant hepatobiliary conditions, including but not limited to non-alcoholic fatty liver disease, cholestatic liver disease (e.g. primary sclerosing cholangitis), and cholangiocarcinoma. Here we provide an overview of fundamental principles, recent discoveries, and potential clinical hepatobiliary applications of this pleiotropic phytocompound.

AB - Curcumin, an aromatic phytoextract from the turmeric (Curcuma longa) rhizome, has been used for centuries for a variety of purposes, not the least of which is medicinal. A growing body of evidence suggests that curcumin has a broad range of potentially therapeutic pharmacological properties, including anti-inflammatory, anti-fibrotic, and anti-neoplastic effects, among others. Clinical applications of curcumin have been hampered by quality control concerns and limited oral bioavailability, although novel formulations appear to have largely overcome these issues. Recent in vitro and in vivo studies have found that curcumin’s cytoprotective and other biological activities may play a role in an array of benign and malignant hepatobiliary conditions, including but not limited to non-alcoholic fatty liver disease, cholestatic liver disease (e.g. primary sclerosing cholangitis), and cholangiocarcinoma. Here we provide an overview of fundamental principles, recent discoveries, and potential clinical hepatobiliary applications of this pleiotropic phytocompound.

KW - Antioxidants

KW - Complementary medicine

KW - Liver diseases

KW - Phytotherapy

UR - http://www.scopus.com/inward/record.url?scp=85031900798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031900798&partnerID=8YFLogxK

U2 - 10.5604/01.3001.0010.5273

DO - 10.5604/01.3001.0010.5273

M3 - Article

VL - 16

SP - 835

EP - 841

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 6

ER -